<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476359</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 017</org_study_id>
    <nct_id>NCT00476359</nct_id>
  </id_info>
  <brief_title>A PK and Salvage Study for Children With HIV-infection</brief_title>
  <official_title>Lopinavir/r Plus Saquinavir Salvage Therapy in HIV-infected Children With NRTI and/or NNRTI Failure: PK and Two-year Treatment Follow up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche for trial and Saquinavir,and Abbott for Kaletra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics (PK) of LPV/r with saquinavir in HIV-1 infected children. To
      evaluate treatment response (clinical, immunological and virological) to LPV/r, SQV in Thai
      children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PK and 24 week data has been published in Pediatric Infectious Diseases Journal. It
      showed that plasma drug concentrations of saquinavir, lopinavir and ritonavir were at the
      higher limits of expected ranges for adult treatment at approved dosages (1000/100 mg BID for
      saquinavir, 400/100 mg BID for lopinavir/r). The regimen was well tolerated and showed
      significant CD4 rise and VL decline at 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensive 0-12h PK sampling for plasma levels of LPV and SQV, and blood sampling. CD4 viral load safety lab every 3 months.</measure>
    <time_frame>96 week</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>double-boosted PI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>double-boosted protease inhibitor combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/r plus saquinavir</intervention_name>
    <description>lopinavir/ritonavir 230/57.5 mg/m2 orally twice daily and saquinavir 50 mg/kg orally twice daily</description>
    <arm_group_label>double-boosted PI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed HIV-1 infection by HIV-DNA PCR if &lt; 18 months old or by HIV ELISA if greater
             than or equal to 18 months old

          2. Subject is less than or equal to 16 years of age at the day of the first dosing.

          3. Subject is failing a current NRTI and/or NNRTI containing regimen and is na√Øve to
             protease inhibitor containing therapy.

          4. Results of biochemistry and haematology testing should be within pre-specified ranges.

          5. Subject is able to swallow capsules

          6. Caretaker(s) is/are able and willing to sign the Informed Consent Form prior to
             screening evaluations.

        Exclusion Criteria:

          1. History of sensitivity/idiosyncrasy to lopinavir, ritonavir, saquinavir or chemically
             related compounds or excipients which may be employed in the trial.

          2. Relevant history or current condition that might interfere with drug absorption,
             distribution, metabolism or excretion.

          3. Inability of both child and caregiver(s) to understand the nature and extent of the
             trial and the procedures required.

          4. Use of any of concomitant medication, including the drug listed below, that may
             interfere with the pharmacokinetics of LPV/r or SQV.

               -  NNRTIs

               -  Rifampicin

               -  Rifabutin

               -  Phenobarbital

               -  Phenytoine

               -  Carbamazepine

               -  Dexamethasone

               -  Ketoconazole

               -  Clarithromycin

          5. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiat Ruxrungtham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIV-NAT, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pope Kosalaraksa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Khon Kaen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chulalongkorn University Hospital, Department of Pediatrics</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The HIV Netherlands Australia Thailand Research Collaboration</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <results_reference>
    <citation>Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, Pancharoen C, Engchanil C, Ruxrungtham K, Burger D; HIV-NAT 017 Study Team. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J. 2005 Oct;24(10):874-9.</citation>
    <PMID>16220084</PMID>
  </results_reference>
  <results_reference>
    <citation>Kosalaraksa P, Engchanil C, Bunupuradah T, Luesomboon W, Sunthornkachit R, Bunruen S, Intasan J, Jupimai T, Hirunwadee N, Lumbiganon P, Ruxrungtham K on behalf of the PREDICT study team. Prevalence of anemia and impact of iron status in Thai and Cambodian HIV infected children with moderate immunosuppression (PREDICT study), poster No. TUPEB 137. Poster presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 22-25, 2007</citation>
  </results_reference>
  <results_reference>
    <citation>Jasper van der Lugt, Torsak Bunupuradah, Pope Kosalaraksa, Thanyawee Puthanakit, Chulapan Engchanil, Waraporn Sakornjun, Meena Gorowara, ROCHE, Kiat Ruxrungtham, David Burger, Jintanat Ananworanich: Therapeutic Drug Monitoring of lopinavir and saquinavir in Thai HIV infected Children. Poster will be presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 3-7, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Torsak Bunupuradah, Pope Kosalaraksa, Chulapan Engchanil, Pitch Boonrak, Tawan Hirunyanulux, Sasiwimol Ubolyam, Pagakrong Lumbiganon, Kiat Ruxrungtham, Emily Labriola-Tompkins, Jintanat Ananworanich, and HIV-NAT 017 Study Team: Efficacy and safety of double boosted SQV/LPV/r combination at 96 weeks in Thai children who have failed NRTI/NNRTI-.based regimens. Abstract # R-143. Abstract will be presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 3-7, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, Mengthaisong T, Mahanontharit A, Lumbiganon P, Tompkins E, Burger D, Ruxrungtham K, Ananworanich J; HIV-NAT 017 Study Team. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Antivir Ther. 2009;14(2):241-8.</citation>
    <PMID>19430099</PMID>
  </results_reference>
  <results_reference>
    <citation>Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J; HIV-NAT 017 Study Team. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediatr Infect Dis J. 2008 Jul;27(7):623-8. doi: 10.1097/INF.0b013e31816b4539.</citation>
    <PMID>18520443</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2007</study_first_submitted>
  <study_first_submitted_qc>May 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lopinavir/r</keyword>
  <keyword>Saquinavir</keyword>
  <keyword>Dual boosted PIs</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>HIV children</keyword>
  <keyword>C min</keyword>
  <keyword>Second line HAART</keyword>
  <keyword>ARV</keyword>
  <keyword>VL failure</keyword>
  <keyword>Dosage</keyword>
  <keyword>To evaluate treatment response</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Saquinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

